1
|
Mehravanfar H, Farhadian N, Abnous K. Indocyanine green-loaded N-doped carbon quantum dot nanoparticles for effective photodynamic therapy and cell imaging of melanoma cancer: In vitro, ex vivo and in vivo study. J Drug Target 2024:1-23. [PMID: 38779708 DOI: 10.1080/1061186x.2024.2358511] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/03/2024] [Accepted: 05/16/2024] [Indexed: 05/25/2024]
Abstract
N-doped carbon quantum dot (CQD) nanoparticle was prepared as a novel nanocarrier with excellent solubility, stability, and high quantum yield to overcome Indocyanine Green (ICG) obstacle in photodynamic therapy (PDT) with simultaneous cell imaging property. Cell culture study and In vivo assessments on the C57BL/6 mice containing melanoma cancer cells was performed. Results showed that CQD size after ICG loading slightly enhanced from 24.55 nm to 42.67 nm. Detection of reactive oxygen species (ROS) test demonstrated that CQD improved ICG photo-stability and ROS generation capacity upon laser irradiation. Cell culture study illustrated that ICG@CQD could decrease the survival rate of melanoma cancer cells of B16F10 cell line from 48% for pure ICG drug to 28% for ICG@CQD. Captured images by confocal microscopy approved more cellular uptake of ICG@CQD and more qualified cell imaging ability of the nanocarrier. In vivo assessments on the C57BL/6 mice containing melanoma cancer cells displayed the obvious inhibitory effect of the tumor growth for ICG@CQD in comparison to free ICG. In vivo fluorescence images confirmed that ICG@CQD accumulates remarkably more than free ICG in the tumor region. In conclusion, ICG@CQD is proposed as an innovative nanocarrier with great potential for PDT and diagnosis.
Collapse
Affiliation(s)
- Hadiseh Mehravanfar
- Ferdowsi University of Mashhad, Faculty of Engineering, Chemical Engineering Department, Iran
| | - Nafiseh Farhadian
- Ferdowsi University of Mashhad, Faculty of Engineering, Chemical Engineering Department, Iran
| | - Khalil Abnous
- Pharmaceutical Research Center, Pharmaceutical Technology Institute, Mashhad University of Medical Sciences, Mashhad, Iran
- Department of Medicinal Chemistry, School of Pharmacy, Mashhad University of Medical Sciences, Mashhad, Iran
| |
Collapse
|
2
|
Rajoriya V, Gupta R, Vengurlekar S, Surendra Singh U. Nanostructured lipid carriers (NLCs): A promising candidate for lung cancer targeting. Int J Pharm 2024; 655:123986. [PMID: 38493842 DOI: 10.1016/j.ijpharm.2024.123986] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/12/2023] [Revised: 02/24/2024] [Accepted: 03/08/2024] [Indexed: 03/19/2024]
Abstract
Lung cancer stands as the foremost health issue and the principal reason for mortality worldwide. It is projected that India will see over 1.73 million new cases and more than 880,000 deaths related to cancer, with lung cancer being a significant contributor. The efficiency of existing chemotherapy procedures is not optimal because of less soluble nature and short half-life of anticancer substances. More precipitated toxicity and non-existence of targeting propensity can lead to severe side effects, non-compliance, and inconvenience for patients. Nonetheless, the domain of nanomedicine has undergone a revolution in the past few years with the advent of novel drug delivery mechanisms that tackle the drawbacks of conventional approaches. Diverse nanoparticle-based drug delivery methods, including liposomes, nanoparticles, nanostructured lipid carrier and solid lipid nanoparticle that encapsulated chemotherapy drugs, are currently employed for efficient lung cancer therapy. NLCs, recognized as the second-generation lipid nanocarriers, are a focused drug delivery mechanism that has garnered significant interest owing to their multitude of advantages such as increased stability, minimal toxicity, prolonged shelf life, superior encapsulation capability, and biocompatible nature. This review focuses on the NLCs carrier system, discussing its preparation methods, types, characterization, applications, and future prospects in lung cancer treatment.
Collapse
Affiliation(s)
- Vaibhav Rajoriya
- University Institute of Pharmacy, Oriental University, Indore, Madhya Pradesh 453555 India.
| | - Ravikant Gupta
- Faculty, University Institute of Pharmacy, Oriental University, Indore, Madhya Pradesh 453555 India
| | - Sudha Vengurlekar
- Faculty, University Institute of Pharmacy, Oriental University, Indore, Madhya Pradesh 453555 India
| | - Upama Surendra Singh
- University Institute of Pharmacy, Oriental University, Indore, Madhya Pradesh 453555 India
| |
Collapse
|
3
|
Silva DF, Melo ALP, Uchôa AFC, Pereira GMA, Alves AEF, Vasconcellos MC, Xavier-Júnior FH, Passos MF. Biomedical Approach of Nanotechnology and Biological Risks: A Mini-Review. Int J Mol Sci 2023; 24:16719. [PMID: 38069043 PMCID: PMC10706257 DOI: 10.3390/ijms242316719] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/12/2023] [Revised: 11/10/2023] [Accepted: 11/20/2023] [Indexed: 12/18/2023] Open
Abstract
Nanotechnology has played a prominent role in biomedical engineering, offering innovative approaches to numerous treatments. Notable advances have been observed in the development of medical devices, contributing to the advancement of modern medicine. This article briefly discusses key applications of nanotechnology in tissue engineering, controlled drug release systems, biosensors and monitoring, and imaging and diagnosis. The particular emphasis on this theme will result in a better understanding, selection, and technical approach to nanomaterials for biomedical purposes, including biological risks, security, and biocompatibility criteria.
Collapse
Affiliation(s)
- Debora F. Silva
- Technological Development Group in Biopolymers and Biomaterials from the Amazon, Graduate Program in Materials Science and Engineering, Federal University of Para, Ananindeua 67130-660, Brazil;
| | - Ailime L. P. Melo
- Technological Development Group in Biopolymers and Biomaterials from the Amazon, Graduate Program in Biotechnology, Federal University of Para, Belem 66075-110, Brazil
| | - Ana F. C. Uchôa
- Pharmaceutical Biotechnology Laboratory (BioTecFarm), Department of Pharmaceutical Sciences, Federal University of Paraíba, João Pessoa 58051-900, Brazil; (A.F.C.U.); (F.H.X.-J.)
| | - Graziela M. A. Pereira
- Pharmaceutical Biotechnology Laboratory (BioTecFarm), Department of Pharmaceutical Sciences, Federal University of Paraíba, João Pessoa 58051-900, Brazil; (A.F.C.U.); (F.H.X.-J.)
| | - Alisson E. F. Alves
- Post-Graduate Program in Bioactive Natural and Synthetic Products, Federal University of Paraíba, João Pessoa 58051-900, Brazil;
| | | | - Francisco H. Xavier-Júnior
- Pharmaceutical Biotechnology Laboratory (BioTecFarm), Department of Pharmaceutical Sciences, Federal University of Paraíba, João Pessoa 58051-900, Brazil; (A.F.C.U.); (F.H.X.-J.)
- Post-Graduate Program in Bioactive Natural and Synthetic Products, Federal University of Paraíba, João Pessoa 58051-900, Brazil;
| | - Marcele F. Passos
- Technological Development Group in Biopolymers and Biomaterials from the Amazon, Graduate Program in Materials Science and Engineering, Federal University of Para, Ananindeua 67130-660, Brazil;
- Technological Development Group in Biopolymers and Biomaterials from the Amazon, Graduate Program in Biotechnology, Federal University of Para, Belem 66075-110, Brazil
| |
Collapse
|
4
|
Ashique S, Garg A, Hussain A, Farid A, Kumar P, Taghizadeh‐Hesary F. Nanodelivery systems: An efficient and target-specific approach for drug-resistant cancers. Cancer Med 2023; 12:18797-18825. [PMID: 37668041 PMCID: PMC10557914 DOI: 10.1002/cam4.6502] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/01/2023] [Revised: 08/16/2023] [Accepted: 08/25/2023] [Indexed: 09/06/2023] Open
Abstract
BACKGROUND Cancer treatment is still a global health challenge. Nowadays, chemotherapy is widely applied for treating cancer and reducing its burden. However, its application might be in accordance with various adverse effects by exposing the healthy tissues and multidrug resistance (MDR), leading to disease relapse or metastasis. In addition, due to tumor heterogeneity and the varied pharmacokinetic features of prescribed drugs, combination therapy has only shown modestly improved results in MDR malignancies. Nanotechnology has been explored as a potential tool for cancer treatment, due to the efficiency of nanoparticles to function as a vehicle for drug delivery. METHODS With this viewpoint, functionalized nanosystems have been investigated as a potential strategy to overcome drug resistance. RESULTS This approach aims to improve the efficacy of anticancer medicines while decreasing their associated side effects through a range of mechanisms, such as bypassing drug efflux, controlling drug release, and disrupting metabolism. This review discusses the MDR mechanisms contributing to therapeutic failure, the most cutting-edge approaches used in nanomedicine to create and assess nanocarriers, and designed nanomedicine to counteract MDR with emphasis on recent developments, their potential, and limitations. CONCLUSIONS Studies have shown that nanoparticle-mediated drug delivery confers distinct benefits over traditional pharmaceuticals, including improved biocompatibility, stability, permeability, retention effect, and targeting capabilities.
Collapse
Affiliation(s)
- Sumel Ashique
- Department of PharmaceuticsPandaveswar School of PharmacyPandaveswarIndia
| | - Ashish Garg
- Guru Ramdas Khalsa Institute of Science and Technology, PharmacyJabalpurIndia
| | - Afzal Hussain
- Department of Pharmaceutics, College of PharmacyKing Saud UniversityRiyadhSaudi Arabia
| | - Arshad Farid
- Gomal Center of Biochemistry and BiotechnologyGomal UniversityDera Ismail KhanPakistan
| | - Prashant Kumar
- Teerthanker Mahaveer College of PharmacyTeerthanker Mahaveer UniversityMoradabadIndia
- Department of Pharmaceutics, Amity Institute of PharmacyAmity University Madhya Pradesh (AUMP)GwaliorIndia
| | - Farzad Taghizadeh‐Hesary
- ENT and Head and Neck Research Center and Department, The Five Senses Health Institute, School of MedicineIran University of Medical SciencesTehranIran
- Clinical Oncology DepartmentIran University of Medical SciencesTehranIran
| |
Collapse
|
5
|
Nicoleti LR, Di Filippo LD, Duarte JL, Luiz MT, Sábio RM, Chorilli M. Development, characterization and in vitro cytotoxicity of kaempferol-loaded nanostructured lipid carriers in glioblastoma multiforme cells. Colloids Surf B Biointerfaces 2023; 226:113309. [PMID: 37054466 DOI: 10.1016/j.colsurfb.2023.113309] [Citation(s) in RCA: 3] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/18/2023] [Revised: 03/09/2023] [Accepted: 04/08/2023] [Indexed: 04/15/2023]
Abstract
Glioblastoma multiforme is the most common and most aggressive human brain cancer. GBM treatment is still a challenge because many drugs are not able to cross the blood-brain barrier, in addition to the increasing resistance to currently available chemotherapy. New therapeutic alternatives are emerging, and, in this context, we highlight kaempferol, a flavonoid with remarkable anti-tumor activity but with limited bioavailability due to its strong lipophilic property. A promising tool to improve the biopharmaceutical properties of molecules such as kaempferol is the use of drug-delivery nanosystems, such as nanostructured lipid carriers (NLC), which can facilitate the dispersion and delivery of highly lipophilic molecules. The present work aimed at the development and characterization of kaempferol-loaded NLC (K-NLC) and the evaluation of its biological properties using in vitro models. The K-NLC showed an average size of 120 nm, zeta potential of - 21 mV, and polydispersity index of 0.099. The K-NLC presented high kaempferol encapsulation efficiency (93%), a drug loading of 3.58%, and a sustained kaempferol release profile for up to 48 h. In addition to presenting a 7-fold increase in kaempferol cytotoxicity, its encapsulation in NLC promoted a cellular uptake of 75%, which corroborates with increased cytotoxicity in U-87MG cells, as observed. Together, these data reinforce the promising antineoplastic properties of kaempferol in addition to the key role of NLC as a platform for the efficient delivery of lipophilic drugs to neoplastic cells, which improved their uptake and therapeutic efficacy in glioblastoma multiforme cells.
Collapse
Affiliation(s)
- Luisa Ribeiro Nicoleti
- São Paulo State University "Júlio de Mesquita Filho", School of Pharmaceutical Sciences, Araraquara 14800903, São Paulo, Brazil
| | - Leonardo Delello Di Filippo
- São Paulo State University "Júlio de Mesquita Filho", School of Pharmaceutical Sciences, Araraquara 14800903, São Paulo, Brazil.
| | - Jonatas Lobato Duarte
- São Paulo State University "Júlio de Mesquita Filho", School of Pharmaceutical Sciences, Araraquara 14800903, São Paulo, Brazil
| | - Marcela Tavares Luiz
- São Paulo State University "Júlio de Mesquita Filho", School of Pharmaceutical Sciences, Araraquara 14800903, São Paulo, Brazil
| | - Rafael Miguel Sábio
- São Paulo State University "Júlio de Mesquita Filho", School of Pharmaceutical Sciences, Araraquara 14800903, São Paulo, Brazil
| | - Marlus Chorilli
- São Paulo State University "Júlio de Mesquita Filho", School of Pharmaceutical Sciences, Araraquara 14800903, São Paulo, Brazil
| |
Collapse
|
6
|
Sartaj A, Annu, Alam M, Biswas L, Yar MS, Mir SR, Verma AK, Baboota S, Ali J. Combinatorial delivery of Ribociclib and Green tea extract mediated nanostructured lipid carrier for oral delivery for the treatment of breast cancer synchronizing in silico, in vitro, and in vivo studies. J Drug Target 2022; 30:1113-1134. [PMID: 35856926 DOI: 10.1080/1061186x.2022.2104292] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/17/2022]
Abstract
Purpose: The current research investigated the development and evaluation of dual drug-loaded nanostructure lipidic carriers (NLCs) of green tea extract and Ribociclib.Method: In silico study were performed to determine the effectiveness of combinational approach. The prepared NLCs were subjected to in vitro drug release, lipolysis, haemolysis and cell line studies to assess their in vivo prospect.Results: In silico study was done to get docking score of EGCG (-8.98) close to Ribociclib (-10.78) in CDK-4 receptors. The prepared NLCs exhibited particle size (175.80 ± 3.51 nm); PDI (0.571 ± 0.012); and %EE [RBO (80.91 ± 1.66%) and GTE 75.98 ± 2.35%)] respectively. MCF-7 cell lines were used to evaluate the MTT assay, cellular uptake and antioxidant (ROS and SOD) of prepared NLCs. In vitro drug release showed the controlled release up to 72 h. In vitro lipolysis and in vitro haemolysis studies showed the availability of drugs at absorption sites and the greater in vivo prospects of NLCs respectively. Pharmacokinetic study revealed a 3.63-fold and 1.53-fold increment in RBO and GTE bioavailability in female Wistar rats respectively.Conclusion: The prominent potential of green tea extract and RBO-loaded NLCs in enhancing their therapeutic efficacy for better treatment of breast cancer.
Collapse
Affiliation(s)
- Ali Sartaj
- Department of Pharmaceutics, School of Pharmaceutical Education and Research, Jamia Hamdard, New Delhi, 110062, India
| | - Annu
- Department of Pharmaceutics, School of Pharmaceutical Education and Research, Jamia Hamdard, New Delhi, 110062, India
| | - Meraj Alam
- Department of Pharmaceutics, School of Pharmaceutical Education and Research, Jamia Hamdard, New Delhi, 110062, India
| | - Largee Biswas
- Nanobiotech Lab, Kirori Mal College, University of Delhi, Delhi, 110007, India
| | - Mohammad Shahar Yar
- Department of Pharmaceutical Chemistry, School of Pharmaceutical Education and Research, Jamia Hamdard, New Delhi, 110062, India
| | - Showkat Rasool Mir
- Department of Pharmacognosy and Phytochemistry, Phytomedicine Laboratory, School of Pharmaceutical Education and Research, Jamia Hamdard, New Delhi, 110062, India
| | - Anita Kamra Verma
- Nanobiotech Lab, Kirori Mal College, University of Delhi, Delhi, 110007, India
| | - Sanjula Baboota
- Department of Pharmaceutics, School of Pharmaceutical Education and Research, Jamia Hamdard, New Delhi, 110062, India
| | - Javed Ali
- Department of Pharmaceutics, School of Pharmaceutical Education and Research, Jamia Hamdard, New Delhi, 110062, India
| |
Collapse
|
7
|
Shete MB, Patil TS, Deshpande AS, Saraogi G, Vasdev N, Deshpande M, Rajpoot K, Tekade RK. Current trends in theranostic nanomedicines. J Drug Deliv Sci Technol 2022. [DOI: 10.1016/j.jddst.2022.103280] [Citation(s) in RCA: 3] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/06/2023]
|
8
|
Nanomedicine-Based Delivery Strategies for Breast Cancer Treatment and Management. Int J Mol Sci 2022; 23:ijms23052856. [PMID: 35269998 PMCID: PMC8911433 DOI: 10.3390/ijms23052856] [Citation(s) in RCA: 24] [Impact Index Per Article: 12.0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/18/2022] [Revised: 03/03/2022] [Accepted: 03/03/2022] [Indexed: 12/12/2022] Open
Abstract
Breast cancer is one of the most common types of cancer among women globally. It is caused by mutations in the estrogen/progesterone receptors and conventional treatment methods are commonly utilized. About 70–80 percent of individuals with the early-stage non-metastatic disease may be cured. Conventional treatment is far less than the optimal ratio, as demonstrated through the high mortality rate of women with this cancer. However, conventional treatment methods like surgery, radiotherapy, and chemotherapy are not as effective as expected and lead to concerns about low bioavailability, low cellular uptake, emerging resistance, and adverse toxicities. A nanomedicine-based approach is a promising alternative for breast cancer treatment. The present era is witnessing rapid advancements in nanomedicine as a platform for investigating novel therapeutic applications and modern intelligent healthcare management strategies. This paper focuses on nanomedicine-based therapeutic interventions that are becoming more widely accepted for improving treatment effectiveness and reducing undesired side effects in breast cancer patients. By evaluating the state-of-the-art tools and taking the challenges involved into consideration, various aspects of the proposed nano-enabled therapeutic approaches have been discussed in this review.
Collapse
|
9
|
Cohen L, Assaraf YG, Livney YD. Novel Selectively Targeted Multifunctional Nanostructured Lipid Carriers for Prostate Cancer Treatment. Pharmaceutics 2021; 14:pharmaceutics14010088. [PMID: 35056984 PMCID: PMC8781189 DOI: 10.3390/pharmaceutics14010088] [Citation(s) in RCA: 3] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/06/2021] [Revised: 12/16/2021] [Accepted: 12/19/2021] [Indexed: 12/13/2022] Open
Abstract
Prostate cancer (PC) is the most common cancer in men over 50 and the 4th most prevalent human malignancy. PC treatment may include surgery, androgen deprivation therapy, chemotherapy, and radiation therapy. However, the therapeutic efficacy of systemic chemotherapy is limited due to low drug solubility and insufficient tumor specificity, inflicting toxic side effects and frequently provoking the emergence of drug resistance. Towards the efficacious treatment of PC, we herein developed novel selectively PC-targeted nanoparticles (NPs) harboring a cytotoxic drug cargo. This delivery system is based upon PEGylated nanostructured lipid carriers (NLCs), decorated with a selective ligand, targeted to prostate-specific membrane antigen (PSMA). NPs loaded with cabazitaxel (CTX) displayed a remarkable loading capacity of 168 ± 3 mg drug/g SA-PEG, encapsulation efficiency of 67 ± 1%, and an average diameter of 159 ± 3 nm. The time-course of in vitro drug release from NPs revealed a substantial drug retention profile compared to the unencapsulated drug. These NPs were selectively internalized into target PC cells overexpressing PSMA, and displayed a dose-dependent growth inhibition compared to cells devoid of the PSMA receptor. Remarkably, these targeted NPs exhibited growth-inhibitory activity at pM CTX concentrations, being markedly more potent than the free drug. This selectively targeted nano-delivery platform bears the promise of enhanced efficacy and minimal untoward toxicity.
Collapse
Affiliation(s)
- Lital Cohen
- The Laboratory of Biopolymers for Food and Health, Department of Biotechnology and Food Engineering, Technion–Israel Institute of Technology, Haifa 3200003, Israel;
| | - Yehuda G. Assaraf
- The Fred Wyszkowski Cancer Research Laboratory, Department of Biology, Technion–Israel Institute of Technology, Haifa 3200003, Israel
- Correspondence: (Y.G.A.); (Y.D.L.)
| | - Yoav D. Livney
- The Laboratory of Biopolymers for Food and Health, Department of Biotechnology and Food Engineering, Technion–Israel Institute of Technology, Haifa 3200003, Israel;
- Correspondence: (Y.G.A.); (Y.D.L.)
| |
Collapse
|
10
|
Wang J, Sun L, Liu J, Sun B, Li L, Xu ZP. Biomimetic 2D layered double hydroxide nanocomposites for hyperthermia-facilitated homologous targeting cancer photo-chemotherapy. J Nanobiotechnology 2021; 19:351. [PMID: 34717639 PMCID: PMC8557519 DOI: 10.1186/s12951-021-01096-9] [Citation(s) in RCA: 10] [Impact Index Per Article: 3.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/24/2021] [Accepted: 10/18/2021] [Indexed: 12/14/2022] Open
Abstract
BACKGROUND Multi-modal therapy has attracted increasing attention as it provides enhanced effectiveness and potential stimulation of the immune community. However, low accumulation at the tumor sites and quick immune clearance of the anti-tumor agents are still insurmountable challenges. Hypothetically, cancer cell membrane (CCM) can homologously target the tumor whereas multi-modal therapy can complement the disadvantages of singular therapies. Meanwhile, moderate hyperthermia induced by photothermal therapy can boost the cellular uptake of therapeutic agents by cancer cells. RESULTS CCM-cloaked indocyanine green (ICG)-incorporated and abraxane (PTX-BSA)-loaded layered double hydroxide (LDH) nanosheets (LIPC NSs) were fabricated for target efficient photo-chemotherapy of colorectal carcinoma (CRC). The CCM-cloaked LDH delivery system showed efficient homologous targeting and cytotoxicity, which was further enhanced under laser irradiation to synergize CRC apoptosis. On the other hand, CCM-cloaking remarkably reduced the uptake of LDH NSs by HEK 293T cells and macrophages, implying mitigation of the side effects and the immune clearance, respectively. In vivo data further exhibited that LIPC NSs enhanced the drug accumulation in tumor tissues and significantly retarded tumor progression under laser irradiation at very low therapeutic doses (1.2 and 0.6 mg/kg of ICG and PTX-BSA), without observed side effects on other organs. CONCLUSIONS This research has demonstrated that targeting delivery efficiency and immune-escaping ability of LIPC NSs are tremendously enhanced by CCM cloaking for efficient tumor accumulation and in situ generated hyperthermia boosts the uptake of LIPC NSs by cancer cells, a potential effective way to improve the multi-modal cancer therapy.
Collapse
Affiliation(s)
- Jingjing Wang
- Australian Institute for Bioengineering and Nanotechnology, The University of Queensland, Brisbane, QLD, 4072, Australia
| | - Luyao Sun
- Australian Institute for Bioengineering and Nanotechnology, The University of Queensland, Brisbane, QLD, 4072, Australia
| | - Jie Liu
- Australian Institute for Bioengineering and Nanotechnology, The University of Queensland, Brisbane, QLD, 4072, Australia
| | - Bing Sun
- Australian Institute for Bioengineering and Nanotechnology, The University of Queensland, Brisbane, QLD, 4072, Australia
| | - Li Li
- Australian Institute for Bioengineering and Nanotechnology, The University of Queensland, Brisbane, QLD, 4072, Australia.
| | - Zhi Ping Xu
- Australian Institute for Bioengineering and Nanotechnology, The University of Queensland, Brisbane, QLD, 4072, Australia.
| |
Collapse
|
11
|
Tao M, Chen J, Huang K. Bio-based antimicrobial delivery systems for improving microbial safety and quality of raw or minimally processed foods. Curr Opin Food Sci 2021. [DOI: 10.1016/j.cofs.2021.04.011] [Citation(s) in RCA: 3] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/18/2022]
|
12
|
Gowsalya K, Yasothamani V, Vivek R. Emerging indocyanine green-integrated nanocarriers for multimodal cancer therapy: a review. NANOSCALE ADVANCES 2021; 3:3332-3352. [PMID: 36133722 PMCID: PMC9418715 DOI: 10.1039/d1na00059d] [Citation(s) in RCA: 17] [Impact Index Per Article: 5.7] [Reference Citation Analysis] [Abstract] [Grants] [Track Full Text] [Subscribe] [Scholar Register] [Received: 01/21/2021] [Accepted: 04/03/2021] [Indexed: 05/17/2023]
Abstract
Nanotechnology is a branch of science dealing with the development of new types of nanomaterials by several methods. In the biomedical field, nanotechnology is widely used in the form of nanotherapeutics. Therefore, the current biomedical research pays much attention to nanotechnology for the development of efficient cancer treatment. Indocyanine green (ICG) is a near-infrared tricarbocyanine dye approved by the Food and Drug Administration (FDA) for human clinical use. ICG is a biologically safe photosensitizer and it can kill tumor cells by producing singlet oxygen species and photothermal heat upon NIR irradiation. ICG has some limitations such as easy aggregation, rapid aqueous degradation, and a short half-life. To address these limitations, ICG is further formulated with nanoparticles. Therefore, ICG is integrated with organic nanomaterials (polymers, micelles, liposomes, dendrimers and protein), inorganic nanomaterials (magnetic, gold, mesoporous, calcium, and LDH based), and hybrid nanomaterials. The combination of ICG with nanomaterials provides highly efficient therapeutic effects. Nowadays, ICG is used for various biomedical applications, especially in cancer therapeutics. In this review, we mainly focus on ICG-based combined cancer nanotherapeutics for advanced cancer treatment.
Collapse
Affiliation(s)
- Karunanidhi Gowsalya
- Bio-Nano Therapeutics Research Laboratory, Cancer Research Program (CRP), School of Life Sciences, Department of Zoology, Bharathiar University Coimbatore-641 046 India
| | - Vellingiri Yasothamani
- Bio-Nano Therapeutics Research Laboratory, Cancer Research Program (CRP), School of Life Sciences, Department of Zoology, Bharathiar University Coimbatore-641 046 India
| | - Raju Vivek
- Bio-Nano Therapeutics Research Laboratory, Cancer Research Program (CRP), School of Life Sciences, Department of Zoology, Bharathiar University Coimbatore-641 046 India
| |
Collapse
|
13
|
Rizwanullah M, Ahmad MZ, Garg A, Ahmad J. Advancement in design of nanostructured lipid carriers for cancer targeting and theranostic application. Biochim Biophys Acta Gen Subj 2021; 1865:129936. [PMID: 34058266 DOI: 10.1016/j.bbagen.2021.129936] [Citation(s) in RCA: 10] [Impact Index Per Article: 3.3] [Reference Citation Analysis] [Abstract] [Key Words] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/19/2020] [Revised: 04/18/2021] [Accepted: 05/24/2021] [Indexed: 12/14/2022]
Abstract
BACKGROUND Cancer development is associated with abnormal, uncontrolled cell growth and causes significant economic and social burdens to society. The global statistics of different cancers have been increasing because of the aging population, and the increasing prevalence of risk factors such as stress condition, overweight, changing reproductive patterns, and smoking. The prognosis of cancer treatment is high, if diagnosed in the early stage. Late-stage diagnosis, however, is still a big challenge for the clinician. The usual treatment scheme involves chemotherapy and surgery followed by radiotherapy. SCOPE OF REVIEW Chemotherapy is the most widely used therapeutic approach against cancer. However, it suffers from the major limitation of poor delivery of anticancer therapeutics to specific cancer-targeted tissues/cells. MAJOR CONCLUSIONS Nanomedicines, particularly nanostructured lipid carriers (NLCs) can improve the efficacy of encapsulated payload either through an active or passive targeting approach against different cancers. The targeted nanomedicine can be helpful in transporting drug carriers to the specifically tumor-targeted tissue/cells while sparing abstaining from the healthy tissue/cells. The active targeting utilizes the binding of a specific cancer ligand to the surface of the NLCs, which improves the therapeutic efficacy and safety of the cancer therapeutics. GENERAL SIGNIFICANCE This review shed light on the utilization of NLCs system for targeted therapy in different cancers. Furthermore, modification of NLCs as cancer theranostics is a recent advancement that is also discussed in the manuscript with a review of contemporary research carried out in this field.
Collapse
Affiliation(s)
- Md Rizwanullah
- Department of Pharmaceutics, School of Pharmaceutical Education and Research, Jamia Hamdard, New Delhi 110062, India
| | - Mohammad Zaki Ahmad
- Department of Pharmaceutics, College of Pharmacy, Najran University, Najran, Saudi Arabia
| | - Anuj Garg
- Institute of Pharmaceutical Research, GLA University, Mathura, U.P., India
| | - Javed Ahmad
- Department of Pharmaceutics, College of Pharmacy, Najran University, Najran, Saudi Arabia.
| |
Collapse
|
14
|
Cohen L, Livney YD, Assaraf YG. Targeted nanomedicine modalities for prostate cancer treatment. Drug Resist Updat 2021; 56:100762. [PMID: 33857756 DOI: 10.1016/j.drup.2021.100762] [Citation(s) in RCA: 20] [Impact Index Per Article: 6.7] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/08/2021] [Revised: 03/16/2021] [Accepted: 03/18/2021] [Indexed: 12/17/2022]
Abstract
Prostate cancer (PC) is the second most common cause of death amongst men in the USA. Therapy of PC has been transformed in the past decade by introducing novel therapeutics, advanced functional imaging and diagnostic approaches, next generation sequencing, as well as improved application of existing therapies in localized PC. Treatment of PC at the different stages of the disease may include surgery, androgen deprivation therapy (ADT), chemotherapy and radiation therapy. However, although ADT has proven efficacious in PC treatment, its effectiveness may be temporary, as these tumors frequently develop molecular mechanisms of therapy resistance, which allow them to survive and proliferate even under conditions of testosterone deprivation, inhibition of androgen receptor signaling, or cytotoxic drug treatment. Importantly, ADT was found to induce key alterations which frequently result in the formation of metastatic tumors displaying a therapy refractory phenotype. Hence, to overcome these serious therapeutic impediments, novel PC cell-targeted therapeutic strategies are being developed. These include diverse platforms enabling specific enhanced antitumor drug uptake and increased intracellular accumulation. Studies have shown that these novel treatment modalities lead to enhanced antitumor activity and diminished systemic toxicity due to the use of selective targeting and decreased drug doses. The underlying mechanism of targeting and internalization is based upon the interaction between a selective ligand, conjugated to a drug-loaded nanoparticle or directly to an anti-cancer drug, and a specific plasma membrane biomarker, uniquely overexpressed on the surface of PC cells. Another targeted therapeutic approach is the delivery of unique anti-oncogenic signaling pathway-based therapeutic drugs, which are selectively cytotoxic to PC cells. The current paper reviews PC targeted modalities reported in the past 6 years, and discusses both the advantages and limitations of the various targeted treatment strategies.
Collapse
Affiliation(s)
- Lital Cohen
- The Laboratory of Biopolymers for Food and Health, Department of Biotechnology and Food Engineering, Technion - Israel Institute of Technology, Haifa, 3200003, Israel
| | - Yoav D Livney
- The Laboratory of Biopolymers for Food and Health, Department of Biotechnology and Food Engineering, Technion - Israel Institute of Technology, Haifa, 3200003, Israel.
| | - Yehuda G Assaraf
- The Fred Wyszkowski Cancer Research Laboratory, Department of Biology, Technion - Israel Institute of Technology, Haifa, 3200003, Israel.
| |
Collapse
|
15
|
Abou Assi R, Abdulbaqi IM, Siok Yee C. The Evaluation of Drug Delivery Nanocarrier Development and Pharmacological Briefing for Metabolic-Associated Fatty Liver Disease (MAFLD): An Update. Pharmaceuticals (Basel) 2021; 14:215. [PMID: 33806527 PMCID: PMC8001129 DOI: 10.3390/ph14030215] [Citation(s) in RCA: 3] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Key Words] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/22/2020] [Revised: 01/22/2021] [Accepted: 01/27/2021] [Indexed: 12/11/2022] Open
Abstract
Current research indicates that the next silent epidemic will be linked to chronic liver diseases, specifically non-alcoholic fatty liver disease (NAFLD), which was renamed as metabolic-associated fatty liver disease (MAFLD) in 2020. Globally, MAFLD mortality is on the rise. The etiology of MAFLD is multifactorial and still incompletely understood, but includes the accumulation of intrahepatic lipids, alterations in energy metabolism, insulin resistance, and inflammatory processes. The available MAFLD treatment, therefore, relies on improving the patient's lifestyle and multidisciplinary pharmacotherapeutic options, whereas the option of surgery is useless without managing the comorbidities of the MAFLD. Nanotechnology is an emerging approach addressing MAFLD, where nanoformulations are suggested to improve the safety and physicochemical properties of conventional drugs/herbal medicines, physical, chemical, and physiological stability, and liver-targeting properties. A wide variety of liver nanosystems were constructed and delivered to the liver, only those that addressed the MAFLD were discussed in this review in terms of the nanocarrier classes, particle size, shape, zeta potential and offered dissolution rate(s), the suitable preparation method(s), excipients (with synergistic effects), and the suitable drug/compound for loading. The advantages and challenges of each nanocarrier and the focus on potential promising perspectives in the production of MAFLD nanomedicine were also highlighted.
Collapse
Affiliation(s)
- Reem Abou Assi
- Thoughts Formulation Laboratory, Discipline of Pharmaceutical Technology, School of Pharmaceutical Sciences, University Sains Malaysia, Minden 11800, Penang, Malaysia;
- Discipline of Pharmaceutical Technology, College of Pharmacy, Al-Kitab University, Altun-Kupri, Kirkuk 36001, Iraq;
| | - Ibrahim M. Abdulbaqi
- Discipline of Pharmaceutical Technology, College of Pharmacy, Al-Kitab University, Altun-Kupri, Kirkuk 36001, Iraq;
- Pharmaceutical Design and Simulation (PhDS) Lab, Discipline of Pharmaceutical Technology, School of Pharmaceutical Sciences, University Sains Malaysia, Minden 11800, Penang, Malaysia
| | - Chan Siok Yee
- Thoughts Formulation Laboratory, Discipline of Pharmaceutical Technology, School of Pharmaceutical Sciences, University Sains Malaysia, Minden 11800, Penang, Malaysia;
| |
Collapse
|
16
|
Pan H, Shi H, Fu P, Shi P, Yang J. Liposomal Dendritic Cell Vaccine in Breast Cancer Immunotherapy. ACS OMEGA 2021; 6:3991-3998. [PMID: 33585776 PMCID: PMC7876850 DOI: 10.1021/acsomega.0c05924] [Citation(s) in RCA: 4] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Received: 12/04/2020] [Accepted: 01/14/2021] [Indexed: 05/24/2023]
Abstract
Cancer vaccine is well recognized as a promising approach for immunotherapy of cancers. Since dendritic cells (DCs) are capable of processing and presenting antigens to initiate the immune response cascade, the development of DC vaccines is considered as a good choice for the treatment of cancer. Herein, a folic acid (FA)-modified liposome was constructed and loaded with chlorin e6 (Ce6) as a DC vaccine (FA-Lipo-Ce6). It was suggested that the loaded Ce6 within FA-Lipo-Ce6 can be activated under laser irradiation. The photodynamic therapy (PDT) of Ce6 was expected to create on-demand reactive oxygen species (ROS) in situ, which causes cell death and trigger the exposure of tumor-associated antigen (TAA). In addition, the produced ROS can mimic the inflammatory responses for the employment of DC for better antigen presentation and immune response. Most importantly, the employment of DC can recognize the exposed TAA to stimulate DC for effective vaccination in situ. Our results demonstrated the powerful capacity of FA-Lipo-Ce6 to induce DC activation, leading to effective suppression of the growth of breast cancers.
Collapse
|
17
|
Gierlich P, Mata AI, Donohoe C, Brito RMM, Senge MO, Gomes-da-Silva LC. Ligand-Targeted Delivery of Photosensitizers for Cancer Treatment. Molecules 2020; 25:E5317. [PMID: 33202648 PMCID: PMC7698280 DOI: 10.3390/molecules25225317] [Citation(s) in RCA: 42] [Impact Index Per Article: 10.5] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/30/2020] [Revised: 10/26/2020] [Accepted: 11/06/2020] [Indexed: 12/12/2022] Open
Abstract
Photodynamic therapy (PDT) is a promising cancer treatment which involves a photosensitizer (PS), light at a specific wavelength for PS activation and oxygen, which combine to elicit cell death. While the illumination required to activate a PS imparts a certain amount of selectivity to PDT treatments, poor tumor accumulation and cell internalization are still inherent properties of most intravenously administered PSs. As a result, common consequences of PDT include skin photosensitivity. To overcome the mentioned issues, PSs may be tailored to specifically target overexpressed biomarkers of tumors. This active targeting can be achieved by direct conjugation of the PS to a ligand with enhanced affinity for a target overexpressed on cancer cells and/or other cells of the tumor microenvironment. Alternatively, PSs may be incorporated into ligand-targeted nanocarriers, which may also encompass multi-functionalities, including diagnosis and therapy. In this review, we highlight the major advances in active targeting of PSs, either by means of ligand-derived bioconjugates or by exploiting ligand-targeting nanocarriers.
Collapse
Affiliation(s)
- Piotr Gierlich
- CQC, Coimbra Chemistry Center, Department of Chemistry, University of Coimbra, 3000-435 Coimbra, Portugal; (P.G.); (A.I.M.); (C.D.); (R.M.M.B.)
- Medicinal Chemistry, Trinity Translational Medicine Institute, Trinity Centre for Health Sciences, Trinity College Dublin, The University of Dublin, St. James’s Hospital, D08W9RT Dublin, Ireland;
| | - Ana I. Mata
- CQC, Coimbra Chemistry Center, Department of Chemistry, University of Coimbra, 3000-435 Coimbra, Portugal; (P.G.); (A.I.M.); (C.D.); (R.M.M.B.)
| | - Claire Donohoe
- CQC, Coimbra Chemistry Center, Department of Chemistry, University of Coimbra, 3000-435 Coimbra, Portugal; (P.G.); (A.I.M.); (C.D.); (R.M.M.B.)
- Medicinal Chemistry, Trinity Translational Medicine Institute, Trinity Centre for Health Sciences, Trinity College Dublin, The University of Dublin, St. James’s Hospital, D08W9RT Dublin, Ireland;
| | - Rui M. M. Brito
- CQC, Coimbra Chemistry Center, Department of Chemistry, University of Coimbra, 3000-435 Coimbra, Portugal; (P.G.); (A.I.M.); (C.D.); (R.M.M.B.)
- BSIM Therapeutics, Instituto Pedro Nunes, 3030-199 Coimbra, Portugal
| | - Mathias O. Senge
- Medicinal Chemistry, Trinity Translational Medicine Institute, Trinity Centre for Health Sciences, Trinity College Dublin, The University of Dublin, St. James’s Hospital, D08W9RT Dublin, Ireland;
| | - Lígia C. Gomes-da-Silva
- CQC, Coimbra Chemistry Center, Department of Chemistry, University of Coimbra, 3000-435 Coimbra, Portugal; (P.G.); (A.I.M.); (C.D.); (R.M.M.B.)
| |
Collapse
|
18
|
Rajpoot K. Lipid-based Nanoplatforms in Cancer Therapy: Recent Advances and Applications. Curr Cancer Drug Targets 2020; 20:271-287. [PMID: 31951180 DOI: 10.2174/1568009620666200115160805] [Citation(s) in RCA: 6] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/22/2019] [Revised: 11/20/2019] [Accepted: 11/27/2019] [Indexed: 12/24/2022]
Abstract
Though modern available cancer therapies are effective, they possess major adverse effects, causing non-compliance to patients. Furthermore, the majority of the polymeric-based medication platforms are certainly not universally acceptable, due to their several restrictions. With this juxtaposition, lipid-based medication delivery systems have appeared as promising drug nanocarriers to replace the majority of the polymer-based products because they are in a position to reverse polymer as well as, drug-associated restrictions. Furthermore, the amalgamation of the basic principle of nanotechnology in designing lipid nanocarriers, which are the latest form of lipid carriers, has tremendous chemotherapeutic possibilities as tumor-targeted drug-delivery pertaining to tumor therapy. Apart from this, it is reported that nearly 40% of the modern medication entities are lipophilic. Moreover, research continues to be efficient in attaining a significant understanding of the absorption and bioavailability of the developed lipids systems.
Collapse
Affiliation(s)
- Kuldeep Rajpoot
- Institute of Pharmaceutical Sciences, Guru Ghasidas Vishwavidyalaya (A Central University), Bilaspur, Chhattisgarh- 495009, India
| |
Collapse
|
19
|
Nanostructured Lipid Carriers for Delivery of Chemotherapeutics: A Review. Pharmaceutics 2020; 12:pharmaceutics12030288. [PMID: 32210127 PMCID: PMC7151211 DOI: 10.3390/pharmaceutics12030288] [Citation(s) in RCA: 183] [Impact Index Per Article: 45.8] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/10/2020] [Revised: 03/07/2020] [Accepted: 03/14/2020] [Indexed: 12/15/2022] Open
Abstract
The efficacy of current standard chemotherapy is suboptimal due to the poor solubility and short half-lives of chemotherapeutic agents, as well as their high toxicity and lack of specificity which may result in severe side effects, noncompliance and patient inconvenience. The application of nanotechnology has revolutionized the pharmaceutical industry and attracted increasing attention as a significant means for optimizing the delivery of chemotherapeutic agents and enhancing their efficiency and safety profiles. Nanostructured lipid carriers (NLCs) are lipid-based formulations that have been broadly studied as drug delivery systems. They have a solid matrix at room temperature and are considered superior to many other traditional lipid-based nanocarriers such as nanoemulsions, liposomes and solid lipid nanoparticles (SLNs) due to their enhanced physical stability, improved drug loading capacity, and biocompatibility. This review focuses on the latest advances in the use of NLCs as drug delivery systems and their preparation and characterization techniques with special emphasis on their applications as delivery systems for chemotherapeutic agents and different strategies for their use in tumor targeting.
Collapse
|
20
|
Docetaxel-loaded ultrasmall nanostructured lipid carriers for cancer therapy: in vitro and in vivo evaluation. Cancer Chemother Pharmacol 2020; 85:731-739. [PMID: 32146495 DOI: 10.1007/s00280-020-04048-6] [Citation(s) in RCA: 6] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/06/2019] [Accepted: 02/20/2020] [Indexed: 01/30/2023]
Abstract
Lack of cancer-targeted delivery of chemotherapeutics is one of the major obstacles for successful cancer therapy. Nanostructured lipid carriers (NLC) have shown great promise in drug-delivery applications since they are highly scalable, biodegradable nanocarriers with high-drug-loading capacity. However, traditional method prepared NLC, the diameter of which range from 80 to 200 nm, is easily blocked and trapped in perivascular regions without further penetration. As a result, ultrasmall NLC with size under 100 nm or lower range are reported to be ideally tumor targeting carrier as it allows for superior tumor accumulation and permeation. Moreover, surface modification of NLC with folic acid (FA) could significantly increase the drug-delivery efficiency through active targeting effect. In our study, an ultrasmall NLC with FA modification (FA-NLC) was prepared to load docetaxel (DTX) for cancer therapy. Our results showed that DTX-loaded FA-NLC comprised of homogeneous particles with size around 30 nm. In addition, it exhibited great colloidal stability, satisfactory drug-loading efficiency, and high biocompatibility in vitro. Meanwhile, in vivo studies indicated that ultrasmall FA-NLC exhibited greater tumor retention and enhanced antitumor effect compared with control.
Collapse
|
21
|
Rahman M, Al-Ghamdi SA, Alharbi KS, Beg S, Sharma K, Anwar F, Al-Abbasi FA, Kumar V. Ganoderic acid loaded nano-lipidic carriers improvise treatment of hepatocellular carcinoma. Drug Deliv 2020; 26:782-793. [PMID: 31357897 PMCID: PMC6711158 DOI: 10.1080/10717544.2019.1606865] [Citation(s) in RCA: 46] [Impact Index Per Article: 11.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/30/2023] Open
Abstract
This work evaluates nano-lipid carrier of ganoderic acid (GA) and molecular docking on various cancer signaling pathways, an attempt to improve the hepatic condition associated with hepatic carcinoma (HCC) induced by diethyl-nitrosamine (DEN) in Wistar rats. Molecular docking mechanism of GA was performed through binding simulation analysis for various cancer signaling pathway, viz., Bcl-2, Pl3K, NF-κB, Akt/PKB, and Stat-3. Double emulsion solvent displacement method was implied for preparation of GA-loaded nano-lipid carrier. GA-NLCs were evaluated for drug loading capacity, entrapment efficiency, particle size, gastric stability, in vitro drug release, cytotoxicity, cellular uptake, and in vivo studies including macroscopical, hepatic injury markers, non-hepatic, biochemical, antioxidant parameters, and histopathological evaluation. HCC was induced by intraperitoneal injection of DEN (200 mg/kg). Both in vivo and molecular docking results were compatible in establishing the alteration in hepatic nodules, hepatic, non-hepatic, and antioxidant parameters, in a significant manner (p < .001) by GA and GA-NLC along with signal alteration of Bcl-2, Pl3K, NF-κB Akt/PKB, and Stat-3 pathway. Histopathological observation confirmed and supported the above result by GA and GA-NLC. On the basis of our results, we can advocate that, GA interferes with various cancer signaling proteins involved in pathogenesis of cancer and was able to cease the progression of disease. Additionally, GA-NLCs proved its chemoprotective effect against the DEN-induced HCC by modulation of hepatic and non-hepatic parameters through various mechanisms.
Collapse
Affiliation(s)
- Mahfoozur Rahman
- a Department of Pharmaceutical Sciences, Shalom Institute of Health & Allied Sciences, Sam Higginbottom University of Agriculture, Technology & Sciences , Allahabad , India
| | | | - Khalid S Alharbi
- c Department of Pharmacology, College of Pharmacy, Jouf University , Sakakah 72341 , Saudi Arabia
| | - Sarwar Beg
- d School of Pharmaceutical Education and Research, Nanomedicine Research Lab, Jamia Hamdard , New Delhi , India
| | - Kalicharan Sharma
- e School of Pharmaceutical Education and Research, Jamia Hamdard , New Delhi , India
| | - Firoz Anwar
- b Department of Biochemistry, Faculty of Science, King Abdulaziz University , Jeddah , Saudi Arabia
| | - Fahad A Al-Abbasi
- b Department of Biochemistry, Faculty of Science, King Abdulaziz University , Jeddah , Saudi Arabia
| | - Vikas Kumar
- f Department of Pharmaceutical Sciences, Faculty of Health Sciences, Natural Product Drug Discovery Laboratory, Sam Higginbottom University of Agriculture, Technology & Sciences , Allahabad , India
| |
Collapse
|
22
|
Mao M, Liu S, Zhou Y, Wang G, Deng J, Tian L. Nanostructured lipid carrier delivering chlorins e6 as in situ dendritic cell vaccine for immunotherapy of gastric cancer. JOURNAL OF MATERIALS RESEARCH 2020; 35:3257-3264. [PMID: 33424109 PMCID: PMC7785780 DOI: 10.1557/jmr.2020.227] [Citation(s) in RCA: 4] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Received: 05/07/2020] [Accepted: 08/03/2020] [Indexed: 05/05/2023]
Abstract
The recent scientific progress has shown the promising effect of the vaccine in immunotherapy of cancer, which relies on the antigen processing/presentation capability of dendritic cells (DCs). As a result, cancer vaccines targeting DC, which also named as DC vaccine, was a hot-spot in vaccine development. Herein, a nanostructured lipid carrier (NLC) was employed to load chlorin e6 (Ce6) to serve as a potential in situ DC vaccine (NLC/Ce6) for effective immunotherapy of gastric cancer. Taking advantage of the photodynamic effect of Ce6 to generate reactive oxygen species (ROS) under laser irradiation, the NLC/Ce6 was able to trigger cell death and expose tumor-associated antigen (TAA). Moreover, mimicking the natural inflammatory response, the ROS can also recruit the DC for the effective processing/presentation of the in situ exposed TAA. As expected, we observed strong capability DC vaccination efficacy of this platform to effectively inhibit the growth of both primary and distant gastric tumors.
Collapse
Affiliation(s)
- Mao Mao
- Department of Gastric Gland Surgery, First Affiliated Hospital of Guangxi Medical University, Nanning, Guangxi, 530021 China
| | - Senfeng Liu
- Department of Gastric Gland Surgery, First Affiliated Hospital of Guangxi Medical University, Nanning, Guangxi, 530021 China
| | - Yiming Zhou
- Department of Gastric Gland Surgery, First Affiliated Hospital of Guangxi Medical University, Nanning, Guangxi, 530021 China
| | - Gonghe Wang
- Department of Gastric Gland Surgery, First Affiliated Hospital of Guangxi Medical University, Nanning, Guangxi, 530021 China
| | - Jianping Deng
- Department of Gastric Gland Surgery, First Affiliated Hospital of Guangxi Medical University, Nanning, Guangxi, 530021 China
| | - Lei Tian
- Department of Gastric Gland Surgery, First Affiliated Hospital of Guangxi Medical University, Nanning, Guangxi, 530021 China
| |
Collapse
|
23
|
Wang K, Cai Z, Fan R, Yang Q, Zhu T, Jiang Z, Ma Y. A tumor-microenvironment-responsive nanomaterial for cancer chemo-photothermal therapy. RSC Adv 2020; 10:22091-22101. [PMID: 35516594 PMCID: PMC9054608 DOI: 10.1039/d0ra04171h] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/09/2020] [Accepted: 06/01/2020] [Indexed: 11/21/2022] Open
Abstract
Taxol (TAX) is a typical anticancer drug that is widely used in clinical treatment of cancer, while gold nanorods (AuNRs) are a kind of well-known material applied for photothermal therapy (PTT). The therapeutic outcome of TAX in chemotherapy is however limited by drug resistance, while AuNRs often show poor accuracy in PTT. To optimize the functions of TAX and AuNRs, we developed a hydrogen peroxide (H2O2)-triggered nanomaterial (LV–TAX/Au@Ag) for combined chemo-photothermal therapy. In normal tissues, TAX is protected in the lipid bilayer and isolated from the surrounding normal cells, while AuNRs are coated with silver shells and show low photothermal capacity. However, after reaching the tumor tissues, the silver shells can be etched by endogenous H2O2 in the tumor microenvironment, and the photothermal properties of AuNRs are then recovered. Meanwhile, the generated oxygen destabilizes the LV, which makes the 100 nm sized nanosystems disassemble into the smaller sized TAX and AuNRs, leading to the deep penetration and direct interaction with tumor tissues. The related in vitro experiments proved the validity of this “turn off/on” effect. Extensive necrosis and apoptosis were observed in the tumor tissues and the proliferation of solid tumor was greatly suppressed due to this combined chemo-photothermal therapy. In addition, no significant damage was found in normal tissues after the treatment of LV–TAX/Au@Ag. Therefore, the strategy to achieve environmental response by modifying the photothermal agents enhanced the efficiency and safety of nanomedicine, which may help improve cancer treatment. Endogenous hydrogen peroxide was utilized to control the release of agents for better tumor therapeutic effect and safety.![]()
Collapse
Affiliation(s)
- Kaiyu Wang
- Department of Physics
- National Laboratory of Solid State Microstructures
- Collaborative Innovation Center of Advanced Microstructures
- Nanjing University
- Nanjing
| | - Zhiyuan Cai
- Department of Physics
- National Laboratory of Solid State Microstructures
- Collaborative Innovation Center of Advanced Microstructures
- Nanjing University
- Nanjing
| | - Rong Fan
- Key Laboratory of Micro-nano Electric Sensing Technology and Bionic Devices
- College of Electronic and Information Engineering
- Yili Normal University
- Yining
- China
| | - Qian Yang
- Key Laboratory of Micro-nano Electric Sensing Technology and Bionic Devices
- College of Electronic and Information Engineering
- Yili Normal University
- Yining
- China
| | - Tao Zhu
- Department of Physics
- National Laboratory of Solid State Microstructures
- Collaborative Innovation Center of Advanced Microstructures
- Nanjing University
- Nanjing
| | - Zhongying Jiang
- Key Laboratory of Micro-nano Electric Sensing Technology and Bionic Devices
- College of Electronic and Information Engineering
- Yili Normal University
- Yining
- China
| | - Yuqiang Ma
- Department of Physics
- National Laboratory of Solid State Microstructures
- Collaborative Innovation Center of Advanced Microstructures
- Nanjing University
- Nanjing
| |
Collapse
|
24
|
Pan H, Sun Y, Cao D, Wang L. Low-density lipoprotein decorated and indocyanine green loaded silica nanoparticles for tumor-targeted photothermal therapy of breast cancer. Pharm Dev Technol 2019; 25:308-315. [PMID: 31820663 DOI: 10.1080/10837450.2019.1684944] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/25/2022]
Affiliation(s)
- Hongying Pan
- Department of Thyroid and Breast Surgery, Danyang People’s Hospital, Danyang, Jiangsu, China
| | - Yi Sun
- Department of Thyroid and Breast Surgery, Danyang People’s Hospital, Danyang, Jiangsu, China
| | - Danxia Cao
- Department of Thyroid and Breast Surgery, Danyang People’s Hospital, Danyang, Jiangsu, China
| | - Lihui Wang
- Central Laboratory, Danyang People’s Hospital, Danyang, Jiangsu, China
| |
Collapse
|
25
|
Zhang X, Li Y, Wei M, Liu C, Yang J. Cetuximab-modified silica nanoparticle loaded with ICG for tumor-targeted combinational therapy of breast cancer. Drug Deliv 2019; 26:129-136. [PMID: 30798640 PMCID: PMC6394284 DOI: 10.1080/10717544.2018.1564403] [Citation(s) in RCA: 43] [Impact Index Per Article: 8.6] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/12/2018] [Revised: 12/19/2018] [Accepted: 12/26/2018] [Indexed: 12/13/2022] Open
Abstract
Combinational therapy is usually considered as a preferable approach for effective cancer therapy. Especially, combinational chemo and photothermal therapy is of particular interest due to its high flexibility as well as efficiency. In this article, we the silica nanoparticles (SLN) were surface conjugated with Cetuximab (Cet-SLN) to target epidermal growth factor receptor (EGFR), a common receptor that usually observed to overexpress in multiple breast cancers. Moreover, the high drug loading capacity of Cet-SLN was employed to encapsulate photothermal agent indocyanine green (ICG) to finally fabricate a versatile drug delivery system (DDS) able to co-deliver Cet and ICG (Cet-SLN/ICG) for combinational chemo-photothermal therapy of breast cancer. The obtained results clearly demonstrated that Cet-SLN/ICG was well-dispersed nanoparticles with preferable stability under physiological condition. Furthermore, due to the conjugation of Cet, Cet-SLN/ICG could target EGFR which overexpress in MCF-7 cells. Most importantly, both in vitro and in vivo results suggested that compared with Cet or ICG alone, the Cet-SLN/ICG showed superior anticancer efficacy. In conclusion, Cet-SLN/ICG could be a potential platform for effective combinational chemo-photothermal therapy for breast cancer.
Collapse
Affiliation(s)
- Xiaoxue Zhang
- Department of Cardiovascular Ultrasonic Diagnosis, the First Affiliated Hospital of China Medical University, Shenyang, China
| | - Yinyan Li
- Department of Ultrasonic Diagnosis, the First Affiliated Hospital of China Medical University, Shenyang, China
| | - Minjie Wei
- Department of Pharmacology, School of Pharmacy, China Medical University, Shenyang, China
| | - Chang Liu
- Department of Radiation Oncology, the First Affiliated Hospital of China Medical University, Shenyang, China
| | - Jun Yang
- Department of Cardiovascular Ultrasonic Diagnosis, the First Affiliated Hospital of China Medical University, Shenyang, China
| |
Collapse
|
26
|
Zhang L, Zuo X, Li S, Sun M, Xie H, Zhang K, Zhou J, Che L, Ma J, Jia Z, Yang F. Synergistic therapy of magnetism-responsive hydrogel for soft tissue injuries. Bioact Mater 2019; 4:160-166. [PMID: 31016272 PMCID: PMC6465584 DOI: 10.1016/j.bioactmat.2019.03.002] [Citation(s) in RCA: 17] [Impact Index Per Article: 3.4] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/15/2019] [Revised: 03/24/2019] [Accepted: 03/25/2019] [Indexed: 12/21/2022] Open
Abstract
Soft tissue injury is very common and associated with pain, tissue swelling and even malformation if not treated on time. Treating methods include cryotherapy, electrical therapy, ultrasound therapy and anti-inflammatory drug, but none of them is completely satisfying. In this work, for a better therapeutic effect, drug therapy and pulsed electromagnetic field (PEMF) therapy were combined. We constructed a drug delivery system using the tetra-PEG/agar hydrogel (PA). By incorporating Fe3O4 NPs into the hydrogel network, a magnetism-responsive property was achieved in the system. The cytotoxicity and in vivo study showed a good biocompatibility of the PA/Fe3O4 hydrogel. A magnetism-controlled release was attained by the incorporation of Fe3O4. Finally, in vivo study showed a better performance of the DS-loaded PA/Fe3O4 compared with the commercially available DS ointment regarding the recovery of the injured soft tissue. Therefore, this magnetism-responsive hydrogel may represent a promising alternative to treat soft tissue injury.
Collapse
Affiliation(s)
- Lining Zhang
- Rehabilitation Medicine Department, PLA General Hospital, Beijing, 100853, China
| | - Xiuqin Zuo
- Rehabilitation Medicine Department, PLA General Hospital, Beijing, 100853, China
| | - Shengjie Li
- Rehabilitation Medicine Department, PLA General Hospital, Beijing, 100853, China
| | - Mi Sun
- Beijing National Laboratory for Molecular Sciences, State Key Laboratory of Polymer Physics & Chemistry, Institute of Chemistry, Chinese Academy of Sciences, Beijing, 100190, China
| | - Huimin Xie
- Rehabilitation Medicine Department, PLA General Hospital, Beijing, 100853, China
| | - Kai Zhang
- Rehabilitation Medicine Department, PLA General Hospital, Beijing, 100853, China
| | - Jikun Zhou
- Rehabilitation Medicine Department, PLA General Hospital, Beijing, 100853, China
| | - Liyun Che
- Rehabilitation Medicine Department, PLA General Hospital, Beijing, 100853, China
| | - Junxuan Ma
- Orthopedic Research Institute, The First Affiliated Hospital of Sun Yat-sen University, Guangzhou, China
- Guangdong Provincial Key Laboratory of Orthopedics and Traumatology, Guangzhou, China
| | - Zishan Jia
- Rehabilitation Medicine Department, PLA General Hospital, Beijing, 100853, China
| | - Fei Yang
- Beijing National Laboratory for Molecular Sciences, State Key Laboratory of Polymer Physics & Chemistry, Institute of Chemistry, Chinese Academy of Sciences, Beijing, 100190, China
- School of Chemistry and Chemical Engineering, University of Chinese Academy of Sciences, Beijing, 100049, China
| |
Collapse
|
27
|
Ni J, Sun Y, Song J, Zhao Y, Gao Q, Li X. Artificial Cell-Mediated Photodynamic Therapy Enhanced Anticancer Efficacy through Combination of Tumor Disruption and Immune Response Stimulation. ACS OMEGA 2019; 4:12727-12735. [PMID: 31460395 PMCID: PMC6682153 DOI: 10.1021/acsomega.9b01881] [Citation(s) in RCA: 7] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Received: 06/24/2019] [Accepted: 07/15/2019] [Indexed: 05/22/2023]
Abstract
Recent studies have identified photodynamic therapy (PDT) as a promising approach for cancer treatment. Here, in this study, we have constructed cancer cell membrane (CCM)-coated silica nanoparticles (SIL) as an artificial cell carrier (CCM/SIL) to effectively deliver chlorin e6 (Ce6), a commonly adopted photodynamic reagent (CCM/SIL/Ce6), to achieve enhanced PDT of cancer. In addition, apart from the generally recognized cytotoxicity induced by reactive oxygen species (ROS), our study also revealed that ROS could further potentiate the loss of intercellular junctions and integrity disruption as a result of down-regulation of VE-cadherin and CD31. Consequently, dendritic cells (DCs) were more readily accumulated to the tumor tissue and became maturated, which secreted tumor necrosis factor-α and interleukin-12 (IL-12) to trigger the following immune responses. Our work not only explored the anticancer feasibility of a new system but also demonstrated the underlining mechanisms responsible for PDT-induced anticancer effects, which offers a new perspective to employ and improve the efficacy of PDT and related systems.
Collapse
Affiliation(s)
- Jiang Ni
- Department of Pharmacy, The
Affiliated Hospital of Jiangnan University (original
Area of Wuxi Third People’s Hospital), No. 585, North Xingyuan Road,
Liang Xi District, Wuxi City 214000, Jiangsu Province, P. R. China
| | - Ying Sun
- Department of Pharmacy, The
Affiliated Hospital of Jiangnan University (original
Area of Wuxi Third People’s Hospital), No. 585, North Xingyuan Road,
Liang Xi District, Wuxi City 214000, Jiangsu Province, P. R. China
| | - Jinfang Song
- Department of Pharmacy, The
Affiliated Hospital of Jiangnan University (original
Area of Wuxi Third People’s Hospital), No. 585, North Xingyuan Road,
Liang Xi District, Wuxi City 214000, Jiangsu Province, P. R. China
| | - Yiqing Zhao
- Department of Pharmacy, The
Affiliated Hospital of Jiangnan University (original
Area of Wuxi Third People’s Hospital), No. 585, North Xingyuan Road,
Liang Xi District, Wuxi City 214000, Jiangsu Province, P. R. China
| | - Qiufang Gao
- Department of Pharmacy, The
Affiliated Hospital of Jiangnan University (original
Area of Wuxi Third People’s Hospital), No. 585, North Xingyuan Road,
Liang Xi District, Wuxi City 214000, Jiangsu Province, P. R. China
| | - Xia Li
- Department of Pharmacy, The
Affiliated Hospital of Jiangnan University (original
Area of Wuxi Third People’s Hospital), No. 585, North Xingyuan Road,
Liang Xi District, Wuxi City 214000, Jiangsu Province, P. R. China
| |
Collapse
|
28
|
Zhang J, Miao Y, Ni W, Xiao H, Zhang J. Cancer cell membrane coated silica nanoparticles loaded with ICG for tumour specific photothermal therapy of osteosarcoma. ARTIFICIAL CELLS NANOMEDICINE AND BIOTECHNOLOGY 2019; 47:2298-2305. [PMID: 31174440 DOI: 10.1080/21691401.2019.1622554] [Citation(s) in RCA: 44] [Impact Index Per Article: 8.8] [Reference Citation Analysis] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 10/26/2022]
Affiliation(s)
- Jingwei Zhang
- Department of Orthopedics, Shanghai Fengxian District Central Hospital / Shanghai University of Medicine & Health Sciences Affiliated Sixth People's Hospital South Campus, Shanghai, China
| | - Yu Miao
- Department of Orthopedics, Shanghai Sixth People’s Hospital, Shanghai, China
| | - Weifeng Ni
- Department of Orthopedics, Shanghai Fengxian District Central Hospital / Shanghai University of Medicine & Health Sciences Affiliated Sixth People's Hospital South Campus, Shanghai, China
| | - Haijun Xiao
- Department of Orthopedics, Shanghai Fengxian District Central Hospital / Shanghai University of Medicine & Health Sciences Affiliated Sixth People's Hospital South Campus, Shanghai, China
| | - Jieyuan Zhang
- Department of Orthopedics, Shanghai Sixth People’s Hospital, Shanghai, China
| |
Collapse
|
29
|
Martinelli C, Pucci C, Ciofani G. Nanostructured carriers as innovative tools for cancer diagnosis and therapy. APL Bioeng 2019; 3:011502. [PMID: 31069332 PMCID: PMC6481740 DOI: 10.1063/1.5079943] [Citation(s) in RCA: 112] [Impact Index Per Article: 22.4] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/05/2018] [Accepted: 03/05/2019] [Indexed: 02/07/2023] Open
Abstract
Cancer accounts for millions of deaths every year and, due to the increase and aging of the world population, the number of new diagnosed cases is continuously rising. Although many progresses in early diagnosis and innovative therapeutic protocols have been already set in clinical practice, still a lot of critical aspects need to be addressed in order to efficiently treat cancer and to reduce several drawbacks caused by conventional therapies. Nanomedicine has emerged as a very promising approach to support both early diagnosis and effective therapy of tumors, and a plethora of different inorganic and organic multifunctional nanomaterials have been ad hoc designed to meet the constant demand for new solutions in cancer treatment. Given their unique features and extreme versatility, nanocarriers represent an innovative and easily adaptable tool both for imaging and targeted therapy purposes, in order to improve the specific delivery of drugs administered to cancer patients. The current review reports an in-depth analysis of the most recent research studies aiming at developing both inorganic and organic materials for nanomedical applications in cancer diagnosis and therapy. A detailed overview of different approaches currently undergoing clinical trials or already approved in clinical practice is provided.
Collapse
Affiliation(s)
- Chiara Martinelli
- Istituto Italiano di Tecnologia, Smart Bio-Interfaces, Pontedera (Pisa) 56025, Italy
| | - Carlotta Pucci
- Istituto Italiano di Tecnologia, Smart Bio-Interfaces, Pontedera (Pisa) 56025, Italy
| | - Gianni Ciofani
- Authors to whom correspondence should be addressed:; ; and
| |
Collapse
|
30
|
Hou KT, Liu TI, Chiu HC, Chiang WH. DOX/ICG-carrying γ-PGA-g-PLGA-based polymeric nanoassemblies for acid-triggered rapid DOX release combined with NIR-activated photothermal effect. Eur Polym J 2019. [DOI: 10.1016/j.eurpolymj.2018.11.038] [Citation(s) in RCA: 15] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/12/2022]
|
31
|
Zhao X, Tang D, Yang T, Wang C. Facile preparation of biocompatible nanostructured lipid carrier with ultra-small size as a tumor-penetration delivery system. Colloids Surf B Biointerfaces 2018; 170:355-363. [DOI: 10.1016/j.colsurfb.2018.06.017] [Citation(s) in RCA: 45] [Impact Index Per Article: 7.5] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/31/2018] [Revised: 05/16/2018] [Accepted: 06/14/2018] [Indexed: 01/01/2023]
|
32
|
Meng LX, Ren Q, Meng Q, Zheng YX, He ML, Sun SY, Ding ZJ, Li BC, Wang HY. Trastuzumab modified silica nanoparticles loaded with doxorubicin for targeted and synergic therapy of breast cancer. ARTIFICIAL CELLS NANOMEDICINE AND BIOTECHNOLOGY 2018; 46:S556-S563. [PMID: 30146920 DOI: 10.1080/21691401.2018.1501380] [Citation(s) in RCA: 18] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 10/28/2022]
Affiliation(s)
- Ling-xin Meng
- Department of Oncology, People's Hospital of Rizhao, Rizhao 276826, China
| | - Qiang Ren
- Department of Pharmacy, Jining Medical University, Rizhao 276826, China
| | - Qin Meng
- Department of Oncology, People's Hospital of Rizhao, Rizhao 276826, China
| | - Yu-xiu Zheng
- Department of Oncology, People's Hospital of Rizhao, Rizhao 276826, China
| | - Mao-lei He
- Department of Oncology, People's Hospital of Rizhao, Rizhao 276826, China
| | - Shu-yan Sun
- Department of Oncology, People's Hospital of Rizhao, Rizhao 276826, China
| | - Zhao-jun Ding
- Department of Oncology, People's Hospital of Rizhao, Rizhao 276826, China
| | - Bing-cheng Li
- Department of Oncology, People's Hospital of Rizhao, Rizhao 276826, China
| | - Hui-yun Wang
- Department of Pharmacy, Jining Medical University, Rizhao 276826, China
| |
Collapse
|
33
|
Zhang Z, Wang X, Li B, Hou Y, Cai Z, Yang J, Li Y. Paclitaxel-loaded PLGA microspheres with a novel morphology to facilitate drug delivery and antitumor efficiency. RSC Adv 2018; 8:3274-3285. [PMID: 35541195 PMCID: PMC9077493 DOI: 10.1039/c7ra12683b] [Citation(s) in RCA: 35] [Impact Index Per Article: 5.8] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/22/2017] [Accepted: 01/08/2018] [Indexed: 12/25/2022] Open
Abstract
A novel morphological PTX-PLGA-MS with microporous surface and porous internal structures to enhance drug loading, delivery and antitumor efficiency.
Collapse
Affiliation(s)
- Zongrui Zhang
- State Key Laboratory of Advanced Technology for Materials Synthesis and Processing
- Wuhan University of Technology
- Wuhan 430070
- China
- Biomedical Materials and Engineering Research Center of Hubei Province
| | - Xinyu Wang
- State Key Laboratory of Advanced Technology for Materials Synthesis and Processing
- Wuhan University of Technology
- Wuhan 430070
- China
- Biomedical Materials and Engineering Research Center of Hubei Province
| | - Binbin Li
- State Key Laboratory of Advanced Technology for Materials Synthesis and Processing
- Wuhan University of Technology
- Wuhan 430070
- China
- Biomedical Materials and Engineering Research Center of Hubei Province
| | - Yuanjing Hou
- State Key Laboratory of Advanced Technology for Materials Synthesis and Processing
- Wuhan University of Technology
- Wuhan 430070
- China
- Biomedical Materials and Engineering Research Center of Hubei Province
| | - Zhengwei Cai
- State Key Laboratory of Advanced Technology for Materials Synthesis and Processing
- Wuhan University of Technology
- Wuhan 430070
- China
- Biomedical Materials and Engineering Research Center of Hubei Province
| | - Jing Yang
- School of Foreign Languages
- Wuhan University of Technology
- Wuhan 430070
- China
| | - Yi Li
- Institute of Textiles and Clothing
- The Hong Kong Polytechnic University
- Kowloon
- P. R. China
| |
Collapse
|